Filing Flows › Mimedx Group (MDXG) › Q2 2026
Mimedx Group (MDXG) Q2 2026 earnings results (second quarter 2026)
10-Q filed Jul 29, 2026
Mimedx Group (MDXG) reported revenue of $64.4M for the second quarter 2026 (Q2 2026), -35% from a year earlier and +9% from the quarter before. Operating margin was -28.7%, net loss $14.8M (23.1% of revenue).
Mimedx Group, Q2 2026: revenue $64.4M (-35% year over year), operating margin -28.7%, net loss $14.8M, operating cash flow −$10.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $64.4M | +9% | -35% |
| Operating profit | −$18.5M | — | -249% |
| Net earnings | −$14.8M | — | -254% |
| Operating cash flow | −$10.0M | -633% | -169% |
What changed
Revenue was $64.4M in Q2 2026, down 35% year over year and up 9% from the previous quarter. Surgical was the largest line at 61% of revenue. Wound lost $39.4M year over year (down 61%), 115% of the total change.
Gross margin was 69.0%, down 12.1 points from Q2 2025. Operating costs exceeded revenue by $18.5M, an operating margin of -28.7%. Operating expenses fell 7% while revenue fell 35%. The quarter ended with a net loss of $14.8M, wider than the previous quarter's $10.9M loss.
Operating cash flow was −$10.0M. Non-cash charges added back $732K of depreciation and amortization and $903K of share-based compensation. Working capital and other items added $3.2M. Capital expenditures of $598K exceeded it, leaving free cash flow of −$10.6M.
Questions
What was Mimedx Group's revenue in the second quarter 2026?
Mimedx Group (MDXG) reported revenue of $64.4M for the second quarter 2026 (Q2 2026), -35% from a year earlier and +9% from the quarter before.
Was Mimedx Group profitable in the second quarter 2026?
Operating loss was $18.5M (-28.7% of revenue) and net loss $14.8M.
Source: Mimedx Group 10-Q on SEC EDGAR.